Arthneeti
AP

Anuh Pharma Ltd

Q2 FY25Pharmaceuticals & Biotechnology

Anuh Pharma Ltd Q2 FY25 Results & Presentation Highlights: Revenue ₹169.35 Cr

Q2 FY25 investor presentation: what the company reported on revenue, margins and projects.

Price₹91
Market cap₹937 Cr
P/E21.2
Updated24 Sept 2026
Read4 min read

Based on Anuh Pharma Ltd's Q2 FY25 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the presentation reports, not management guidance.

The short version

Q2 FY25 Revenue: Rs 169.35 Cr (Page 6) - Q2 FY24 Revenue (implied from Q1 FY25): Rs 141.62 Cr (Page 6) - Quarter-over-quarter growth: 20% (Page 6) - H1 FY25 Operating Revenue: Rs 303.86 Cr vs. EBITDA for Q2 FY25: Rs.

From Anuh Pharma Ltd's Q2 FY25 earnings-call transcript · updated 24 Sept 2026.

Revenue & Sales Performance

  • Q2 FY25 Revenue: Rs 169.35 Cr (Page 6)
  • Q2 FY24 Revenue (implied from Q1 FY25): Rs 141.62 Cr (Page 6)
  • Quarter-over-quarter growth: 20% (Page 6)
  • H1 FY25 Operating Revenue: Rs 303.86 Cr vs. Rs 311.01 Cr in H1 FY24, a -2.30% YoY decline (Page 13)
  • Export sales and domestic sales revenue shown for H1 FY25 but no exact figures for Q2 (Page 9)
  • Capacity expansion from 1800 MTPA to 2200 MTPA (Page 6)
  • Future outlook includes growing contributions from new geographies (Japan, Vietnam, South Korea), increasing market share in Corticosteroids (capacity enhanced to 12 MTPA), tapping European market with CEP approvals, and Sulfadoxine institutional business opportunities (Page 29)

2 more points management made on revenue & sales performance

Profitability & Margins

See what Anuh Pharma Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

  • Capital expenditure of Rs. 20 Crore made to expand capacity at the current location (Page 6).
  • Capacity increased from 1800 MTPA to 2200 MTPA as a result of this capex (Page 6).
  • Increased capacity was made ready for commercialization by mid-November 2024 (Page 6).

2 more points management made on capital expenditure plans

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

5x potential
1KRM Ayurveda Ltd
Rev 1Mar 1
2Accretion Pharmaceuticals Ltd
Rev 1Mar 2
3
Rev 1Mar 3
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Anuh Pharma Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

The investor presentation does not explicitly report any details on order book, order inflow, or pending orders. Specifically: - There is no mention of "order book" or "pending orders" figures or status anywhere in the presentation. - The financial and operational highlights focus on revenue, profit, capacity expansion, product launches, management details, shareholding pattern, and future outlook but do not discuss order backlog or inflow. - The presentation emphasizes recent revenue growth, capacity increments, and market expansion without referencing order-related metrics. Therefore, based strictly on the presentation, no data or commentary on order book, order inflow, or pending orders has been provided.

Anuh Pharma Ltd — Quarterly revenue & net profit

Revenue Net profit
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026

Reported quarterly figures (₹ Cr). Latest: revenue ₹202 Cr, net profit ₹12 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Continue your research

What Anuh Pharma Ltd's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

  • Wockhardt Ltd (Q2 FY25)

    Q1 FY25 total income reported at INR 747 Cr., a 14% growth year-on-year versus Q1 FY24 income of INR 658 Cr. Key investor presentation takeaways from Wockhardt

  • Themis Medicare Ltd (Q2 FY25)

    117.01 Cr, up 11.67% YoY from Rs. Key investor presentation takeaways from Themis Medicare Ltd's Q2 FY25 investor presentation — and how it ranks against sector

  • Lincoln Pharmaceuticals Ltd (Q2 FY25)

    EBITDA**: ₹1,234 crore, up 15% YoY . Key investor presentation takeaways from Lincoln Pharmaceuticals Ltd's Q2 FY25 investor presentation — and how it ranks aga

  • Fermenta Biotech Ltd (Q2 FY25)

    Standalone: INR 895 Mn, a 74.5% YoY increase (from INR 513 Mn in Q2-FY24) (Page 9) . Key investor presentation takeaways from Fermenta Biotech Ltd's Q2 FY25 inv

Compare:vs Sun Pharma.Inds.vs Divi's Lab.vs Torrent Pharmaceuticals Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Frequently Asked Questions

What were Anuh Pharma Ltd Q2 FY25 results?

Q2 FY25 Revenue: Rs 169.35 Cr (Page 6) - Q2 FY24 Revenue (implied from Q1 FY25): Rs 141.62 Cr (Page 6) - Quarter-over-quarter growth: 20% (Page 6) - H1 FY25 Operating Revenue: Rs 303.86 Cr vs. EBITDA for Q2 FY25: Rs.

What is Anuh Pharma Ltd share price analysis?

Anuh Pharma Ltd currently shows a neutral. The stock trades at a P/E of 21.2 with a market cap of ₹937 Cr. Investors should review the full earnings analysis for detailed insights.

Is Anuh Pharma Ltd planning capital expenditure?

Capital expenditure of Rs.

Keep Anuh Pharma Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.